|[February 17, 2017]
Global Depression API Manufacturers, Marketed and Phase III Drugs Landscape 2017 - Research and Markets
Research and Markets has announced the addition of the "Depression
- Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017"
drug pipelines to their offering.
Depression - Global API Manufacturers, Marketed and Phase III Drugs
Landscape, 2017, provides comprehensive insights about the marketed
drugs, drug sales, Phase III pipeline drugs and their API Manufacturers
across the globe.
A key objective of the Depression Report is to understand the market and
pipeline status of the drugs around the Depression to explore the
generic development opportunities, licensing opportunities and to gain
competitive advantage on designing pipeline strategies. The Repot
provides the historical and forecasted sales of the drugs till 2018.
The Depression Report gives insights into patents providing the patent
protection data and marketing exclusivity of all the drugs across the
While the leading brands, companies and chemicals are considered
thoroughly, the report also provides details on the Global API
Manufacturers across the globe covering Drug Master Filings of US,
Europe and API Manufacturers in Asia specifically China and India.
Key Topics Covered:
1. Indication Overview
2. Market Drugs Landscape
3. Global API Manufacturers Assessment
4. Phase III Drugs Landscape
5. Drugs Market Data and Forecasted Sales Figure-2018
6. Marketed Drugs for Depression
7. Phase III Drugs for Depression
8. Discontinued Drugs for Depression
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/jdsn37/depression
View source version on businesswire.com: http://www.businesswire.com/news/home/20170217005615/en/
[ Back To TMCnet.com's Homepage ]